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Oncogenic mutations of the MLL histone methyltransferase confer an unusual ability to transform
non-self-renewing myeloid progenitors into leukemia stem cells (LSCs) by mechanisms that remain poorly
defined. Misregulation of Hox genes is likely to be critical for LSC induction and maintenance but alone it
does not recapitulate the phenotype and biology of MLL leukemias, which are clinically heterogeneous—
presumably reflecting differences in LSC biology and/or frequency. TALE (three-amino-acid loop extension)
class homeodomain proteins of the Pbx and Meis families are also misexpressed in this context, and we thus
employed knockout, knockdown, and dominant-negative genetic techniques to investigate the requirements
and contributions of these factors in MLL oncoprotein-induced acute myeloid leukemia. Our studies show
that induction and maintenance of MLL transformation requires Meis1 and is codependent on the redundant
contributions of Pbx2 and Pbx3. Meis1 in particular serves a major role in establishing LSC potential, and
determines LSC frequency by quantitatively regulating the extent of self-renewal, differentiation arrest, and
cycling, as well as the rate of in vivo LSC generation from myeloid progenitors. Thus, TALE proteins are
critical downstream effectors within an essential homeoprotein network that serves a rate-limiting regulatory
role in MLL leukemogenesis.
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Leukemia stem cells (LSCs) comprise a functionally dis-
tinct subpopulation of leukemic cells with the ability to
self-renew extensively, and to initiate, sustain, or regen-
erate disease. In acute myeloid leukemia (AML), LSCs
are generally considered to be rare upstream cells that
arise out of the normal hematopoietic stem cell (HSC) or
primitive progenitor compartments, and are organized in
a hierarchy based on quantitative differences in their
self-renewal potentials (Passegue and Weisman 2005).
This paradigm, however, may not apply to all myeloid
leukemias, as suggested by recent studies using a mouse
model of AML induced by the MLL-AF9 oncogene
(Krivtsov et al. 2006; Somervaille and Cleary 2006),
which is typically associated with FAB-M4 or M5 sub-
types of human AML (Swansbury 1998). LSCs were
found to be very frequent and representative of down-
stream myeloid lineage cells that ectopically acquired
extensive self-renewal and other biologic properties
more typical of HSCs. The key regulators and subordi-
nate genetic programs by which MLL converts myeloid
progenitors into LSCs are of major interest.
MLL is a histone methyltransferase with features sug-
gestive of a general transcriptional role at most promot-
ers (Guenther et al. 2005); however, Hox genes appear to
be particularly dependent on its function (Yu et al. 1995).
In leukemias harboring MLL-activating mutations, sev-
eral Hoxa genes are consistently expressed at high levels,
suggesting that MLL oncoproteins inappropriately main-
tain their expression and prevent their programmed
down-regulation that otherwise accompanies terminal
myeloid differentiation (Imamura et al. 2002b; Pineault
et al. 2002). Since various Hox genes have been impli-
cated in the regulation of normal stem cell self-renewal,
their misregulation in MLL leukemias is likely to be im-
portant for LSC maintenance. Hoxa9, in particular, has
been shown to critically influence MLL oncogenesis (Ay-
ton and Cleary 2003; Kumar et al. 2004; So et al. 2004;
Okada et al. 2005; J. Wang et al. 2005). However, Hox
gene misregulation alone does not recapitulate the bio-
logical and clinical features of MLL leukemia.
Additional candidate factors that may critically regu-
late LSC potentials in MLL leukemias are TALE (three-
amino-acid loop extension) class homeodomain proteins
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of the Pbx and Meis families. They enhance the rela-
tively nonspecific DNA-binding properties of Hox tran-
scription factors and regulate gene expression as hetero-
oligomeric complexes with Hox proteins (Mann 1995).
TALE proteins are required for the execution of some
Hox-dependent developmental programs and are impli-
cated in leukemogenesis (Azpiazu and Morata 1998;
Ryoo et al. 1999; Selleri et al. 2001; Manley et al. 2004;
Eklund 2007; Rice and Licht 2007). Notably, mutations
of Hoxa9 that prevent interactions with Pbx proteins ab-
rogate its oncogenic properties (Schnabel et al. 2000).
Furthermore, coexpression of Meis1 markedly shortens
the latency and increases the penetrance of Hoxa9-in-
duced myeloid leukemia, and recapitulates some of the
features of MLL leukemia (Kroon et al. 1998; Calvo et al.
2001; Zeisig et al. 2004; G.G. Wang et al. 2005). Since
Meis1 is also a transcriptional target of MLL oncopro-
teins and is consistently highly expressed in MLL leuke-
mias (Lawrence et al. 1999; Imamura et al. 2002b; Milne
et al. 2005), simultaneous misregulation of Hoxa9 and
Meis1 may be sufficient for MLL oncogenesis (Zeisig et
al. 2004). However, MLL leukemias are biologically and
clinically diverse, and the specific roles of TALE proteins
in regulating LSC properties that underlie these differ-
ences have not been defined.
In this report, we demonstrate that TALE homeodo-
main proteins are essential for the induction and main-
tenance of MLL leukemogenesis. Meis1, in particular,
quantitatively regulates the differentiation arrest, cy-
cling activity, in vivo progression, and self-renewal of
MLL leukemia cells, thereby functioning as a critical and
rate-limiting determinant of LSC potential.
Results
The latencies of MLL leukemias correlate with Meis1
endogenous expression levels
Twelve different MLL fusion oncoproteins were investi-
gated for their TALE protein-dependent oncogenic prop-
erties. These included MLL oncoproteins containing dif-
ferent classes of fusion partners including cytoplasmic
proteins (GAS7, AF1P, AF6, and EB1), nuclear proteins of
the forkhead family (FKHRL1 and AFX) or AF4 family/
complex (LAF4, AF5, ENL, AF9, and AF10), and histone
modifiers (CBP), which induce leukemia with widely
varying latencies and morphologies in mice (Lavau et al.
1997, 2000; DiMartino et al. 2002; So et al. 2003, 2004; J.
Wang et al. 2005; Somervaille and Cleary 2006; our un-
published observations). E2A-HLF served as a control,
since it transforms myeloid progenitors through Hox-
independent pathways (Ayton and Cleary 2003; So et al.
2004). Retroviral constructs for each of the respective
MLL fusion cDNAs expressed proteins that migrated at
their predicted molecular weights in Western blot analy-
sis (Supplementary Fig. 1A).
Primary murine myeloid progenitors (c-kit+) trans-
duced by the 12 MLL fusion constructs, but not empty
vector, formed colonies in methylcellulose that replated
through at least four rounds of culture (data not shown),
demonstrating the enhanced self-renewal and impaired
differentiation typically induced by MLL oncogenes (La-
vau et al. 1997, 2000). Real-time quantitative PCR analy-
sis of cells from fourth-round cultures showed that
Hoxa5, Hoxa7, Hoxa9, and Hoxa10 were highly ex-
pressed in myeloid cells transduced by MLL oncogenes
compared with control (E2A-HLF) cells under our experi-
mental conditions (Supplementary Fig. 1B,C). The rela-
tive and absolute levels of these Hox transcripts were
fairly uniform, and did not appear to distinguish the dif-
ferent molecular subtypes of MLL-transformed cells.
Conversely, absolute Meis1 expression levels varied
considerably among the different MLL-transformed cells,
from twofold to 40-fold the levels detected in control
(E2A-HLF) cells (Fig. 1A). Meis2 and Meis3 were also
expressed, but not consistently increased relative to
their levels in cells transformed by E2A-HLF, such that
Meis1 accounted for 75%–95% of total Meis transcripts
in MLL-transformed cells (Fig. 1B). Interestingly, Meis1
transcript levels showed a significant correlation with
the latencies for MLL leukemia (Fig. 1C; Supplementary
Table 1). Cells transformed by MLL fusion proteins that
induce a short latency AML in murine models displayed
higher levels of Meis1 expression, whereas those that
induce AML with prolonged latencies displayed lower
levels of Meis1 expression. Statistical analysis showed a
power relationship, indicating that Meis1 transcript lev-
els decreased at a specific rate with respect to increasing
time required for leukemia development. Conversely,
Hoxa9 expression levels showed no correlation with leu-
kemia latencies (Supplementary Fig. 2). These results
suggested that Meis1 likely serves a critical and poten-
tially rate-limiting role in the pathogenesis of MLL leu-
kemia.
Meis1 is essential for induction and maintenance
of MLL-mediated transformation
To specifically address the requirement for Meis1 in
MLL-mediated oncogenesis, transformation assays were
performed using fetal liver (FL) cells isolated from
Meis1−/− embryos at embryonic day 13.5 (E13.5), prior to
their intrauterine demise at approximately E14 (Hisa et
al. 2004). Meis1-deficient FL cells were efficiently trans-
formed by the control E2A-HLF gene; however, none of
the MLL oncogenes was capable of inducing sustained
replating (Fig. 2A). Rather, the plating capacities of MLL-
transduced cells were exhausted after the second round.
Meis1−/− second-round colonies were small in size with a
diffuse morphology and contained markedly reduced
numbers of myeloid blasts when compared with trans-
formed colonies from wild-type FL (Fig. 2B). Conversely,
all tested MLL oncogenes induced continued replating of
E13.5 FL cells isolated from wild-type mice. Moreover,
transformation of Meis1−/− FL cells by MLL-AF9 was res-
cued by cotransduction of Meis1 (Fig. 2A), demonstrating
that the progenitors susceptible to MLL transformation
were present in Meis1−/− FLs at E13.5. Thus, in the ab-
sence of Meis1, MLL oncogenes are incapable of inducing
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GENES & DEVELOPMENT 2763
 Cold Spring Harbor Laboratory Press on August 30, 2018 - Published by genesdev.cshlp.orgDownloaded from 
the enhanced self-renewal and impaired differentiation
necessary for myeloid transformation.
To assess whether Meis1 was required for mainte-
nance of MLL-mediated transformation, wild-type cells
stably transformed by MLL oncogenes were secondarily
transduced with lentiviral vectors expressing short hair-
pin RNAs (shRNAs) to specifically silence Meis1
(Supplementary Fig. 3). Expression of two different Meis1
shRNAs resulted in substantial impairment (>70%–80%)
of clonogenic capacity compared with MLL-transformed
cells secondarily transduced with lentiviral vector
alone (Fig. 2C). Similarly, MLL-transformed cells dis-
played a marked reduction in clonogenic capacity
(>80%) when secondarily transduced with a dominant-
negative construct that lacked the Meis1 DNA-binding
homeodomain, whereas E2A-HLF-transformed cells
were unaffected (Fig. 2D). Therefore, Meis1 is essential
for both the initiation and maintenance of enhanced self-
renewal imposed on myeloid progenitors by MLL onco-
genes.
MEIS1 has been reported to be consistently expressed
in human MLL leukemias (Imamura et al. 2002b; Fer-
rando et al. 2003; Quentmeier et al. 2004), suggesting
that it may serve a similar role in their maintenance.
Quantitative RT–PCR analysis showed that MEIS1 was
expressed in leukemia cell lines with MLL chromosomal
translocations (Fig. 2E). However, in contrast with mu-
rine MLL-transformed cells, MEIS2 was also substan-
tially expressed and ML2 cells were notable for express-
ing 10-fold more MEIS2 versus MEIS1 (Fig. 2E). Lentivi-
ral transduction of two different MEIS1 shRNAs resulted
in substantial impairment (∼40%–60%) of clonogenic ca-
pacity for MLL leukemia cell lines compared with con-
trol K562 cells with the exception of ML2 cells, which
were not significantly compromised (Fig. 2F). Thus, de-
spite the redundancy of MEIS gene expression, our re-
sults suggest that it is nevertheless required to maintain
human MLL leukemias.
Hyperexpression of Meis1 accelerates the progression
of MLL leukemogenesis
The observed correlation of endogenous Meis1 expres-
sion levels with leukemia latency and the requirement
of Meis1 for MLL-mediated stem and progenitor cell
transformation raised the possibility that Meis1 may di-
Figure 1. Meis1 expression levels correlate with the latencies of MLL leukemias. (A) The expression levels of Meis1, Meis2, and Meis3
transcripts were determined by real-time PCR analysis of MLL-transformed cells (indicated below) from the fourth round of serial
replating (error bars indicate standard deviations of triplicate analyses). Results are expressed relative to levels observed in cells
transformed by E2A-HLF (dashed line). (B) Bar graph indicates the total relative levels of Meis transcripts expressed in cells transformed
by various oncogenes (indicated at bottom) from the fourth round of plating in methylcellulose cultures. The relative abundance of
Meis transcripts was determined using the cycle time (Ct) value method, assuming that all primers were optimized to generate equal
PCR efficiencies. (C) The relative expression levels of Meis1 are plotted against median latency times required for leukemia induction
by the respective MLL oncogenes. Latency data are derived in part from the current study as well as published studies (Supplementary
Table 1). The data display a power trend line best-fit (R2 = 0.8053) indicating that Meis1 expression levels decrease at a specific rate
with respect to the time required for leukemia development.
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rectly influence the in vivo generation of LSCs from my-
eloid progenitors, which requires undefined secondary
alterations (Lavau et al. 2000; Somervaille and Cleary
2006). To investigate this possibility, Meis1 was hyper-
expressed along with representative MLL oncogenes
(MLL-AF10, MLL-GAS7, or MLL-LAF4) to determine
Figure 2. Meis1 is required for initiation and maintenance of MLL-mediated myeloid transformation. (A) FL cells from wild-type (left)
or Meis1−/− (right) mice were transduced with fusion oncogenes (indicated on left) and serially plated in methylcellulose cultures every
5 d. Results are shown as colony numbers per 104 plated cells for each round of culture. Data are also shown for Meis1−/− cells
cotransduced with MLL-AF9 and Meis1. Error bars indicate standard deviations of three independent experiments. (B) Cytospin
preparations of wild-type (left) or Meis1−/− (right) FL cells transduced with MLL-AF9 were analyzed for the proportions of cells at the
end of the second round of plating in methylcellulose culture with morphological features of blasts versus differentiation (May
Grunwald Giemsa staining). Bar graph indicates the mean number of cells with the indicated morphologic features (n = 4). Insets show
colony morphologies at the end of the second round. (C) Myeloid progenitors transformed by various MLL oncogenes (indicated on left)
were secondarily transduced with lentiviral vectors encoding shRNAs specific for Meis1 (M1 #1 or M1 #2). Colony numbers are shown
relative to cells secondarily transduced with lentiviral vector alone. Error bars indicate standard deviations of at least two independent
experiments. (D) Myeloid progenitors transformed by various oncogenes (indicated on left) were secondarily transduced with a
dominant-negative Meis1 construct (Meis1 DN). Colony numbers are shown relative to cells transformed by E2A-HLF. Error bars
indicate standard deviations of at least two independent experiments. (E) Bar graph indicates the total relative levels of MEIS1 and
MEIS2 transcripts expressed in human leukemia cell lines (indicated at bottom). The relative abundance of MEIS transcripts was
determined using the Ct value method, assuming that all primers were optimized to generate equal PCR efficiencies. (F) Human
leukemia cell lines (indicated on left) were transduced with lentiviral vectors encoding shRNAs specific for MEIS1 (M1 #b or M1 #c).
Colony numbers are shown relative to cells transduced with lentiviral vector alone. Error bars indicate standard deviations of at least
two independent experiments.
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whether its enhanced expression may accelerate MLL
leukemogenesis. Myeloid progenitors (c-kit+) cotrans-
duced with an MLL oncogene plus Meis1 (MLL/Meis1)
displayed Meis1 transcript levels that were several-fold
higher than progenitors cotransduced with the respec-
tive MLL oncogene plus empty vector (MLL/v) prior to
transplantation (Fig. 3A). Following transplantation of
equal numbers of cotransduced cells (representing com-
parable numbers of colony-forming cells [CFCs]) into
syngeneic recipient mice, the MLL/Meis1 cohorts devel-
oped leukemia with substantially shortened latencies
compared with mice transplanted with MLL/v cotrans-
duced cells (Fig. 3B). Leukemias in both cohorts appeared
grossly similar pathologically—with effacement of the
normal bone marrow architecture, marked spleno-
megaly, and infiltration of the liver by leukemia cells—
and maintained similar levels of Meis1 when compared
with the respective primary cotransduced progenitors
(data not shown). Therefore, Meis1 serves a rate-limiting
role in progression of MLL-associated leukemia.
Meis1 modulates the differentiation arrest,
self-renewal, and cell cycle activity of MLL
leukemia cells
FACS analysis demonstrated that all leukemias were do-
nor-derived (data not shown) and consistently displayed
myeloid phenotypes (Mac1+ Gr1+). However, a greater
fraction of MLL/Meis1 leukemia cells expressed high-
level c-kit and lower Mac1, suggestive of less differen-
tiation (Fig. 4A). Morphologic assessment of splenocytes
obtained at necropsy of MLL/Meis1 mice revealed a sev-
eral-fold higher proportion of cells with cytologic fea-
tures of blasts and substantially fewer differentiating
forms (Fig. 4B) compared with splenocytes from MLL/v
mice. Furthermore, in semisolid culture assays, the fre-
quencies of CFCs in the spleens of leukemic mice were
up to sevenfold higher for MLL/Meis1 leukemias (Fig.
4C) and colony morphologies (Lavau et al. 1997) were
predominantly type I for MLL/Meis1 CFCs, compared
with mostly type II/III for MLL/v CFC (72% vs. 21% for
MLL-AF10 leukemias) (data not shown). Thus, MLL leu-
kemias where Meis1 was overexpressed exhibited a more
pronounced block in differentiation as well as a higher
frequency of clonogenic leukemia cells.
Cell cycle analysis of explanted leukemia cells grow-
ing in methylcellulose cultures revealed a significant in-
crease in the proportion of S/G2/M-phase cells for MLL/
Meis1 versus MLL/v leukemias (Fig. 5A). The higher
fraction of cells in cycle correlated with substantially
lower transcript levels for the CDK inhibitor p16Ink4a,
whereas expression of several other cell cycle regulators
including p19Arf, an alternatively spliced Ink4a tran-
script that codes for a positive regulator of the p53 path-
way, did not differ significantly between MLL/v and
MLL/Meis1 leukemias (Fig. 5B). However, expression of
Bmi-1, a negative regulator of the Ink4a locus (Jacobs et
al. 1999), was significantly higher in MLL/Meis1 leuke-
mias (Fig. 5B). The changes in gene expression as well as
latency were more pronounced in MLL-AF10 versus
MLL-LAF4 leukemias. Therefore, the enabling effects of
Meis1 on proliferation and arrested differentiation of
MLL leukemia cells correlated with specific perturba-
tions of the Bmi-1/Ink4a axis, which is implicated in
maintenance of HSC and LSC self-renewal (Lessard and
Sauvageau 2003; Park et al. 2003).
Figure 3. Increased Meis1 expression accelerates MLL-mediated leukemogenesis. (A) Meis1 transcript levels in myeloid progenitors
(c-kit+) were determined by quantitative real-time PCR 24 h following transduction with retroviruses encoding the MLL oncogenes
indicated above the panel, with or without cotransduced Meis1 (indicated below). Data are expressed relative to the level observed in
cells transduced with MLL oncogene alone (bars indicate the average of triplicate analyses). (B) Survival curves are shown for cohorts
of mice transplanted with cells cotransduced with the indicated MLL oncogene and Meis1 or empty vector. Acute leukemia was
confirmed by peripheral blood leukocyte counts, FACS analyses, and/or necropsy.
Wong et al.
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Meis1 determines MLL LSC frequency
Previous studies of MLL-AF9 AML showed that CFCs
present in the spleens of leukemic mice have the bio-
logical properties of LSCs (Somervaille and Cleary 2006).
To test if the increased CFC frequencies in leukemias
induced by coexpressed exogenous Meis1 also correlated
with increased numbers of LSCs, individual CFCs (type I
or II) were plucked from methylcellulose media and
transplanted into syngeneic mice (or expanded in semi-
solid culture prior to transplant) to assess their potential
to initiate AML in secondary recipients, a hallmark fea-
ture of LSCs. All transplanted mice succumbed to AML
regardless of whether the transplanted CFCs derived
from primary leukemias with or without coexpressed ex-
ogenous Meis1 (Fig. 4D). These results confirmed that
CFCs in each cohort were a reliable indicator of LSCs,
and demonstrated sevenfold higher LSC frequencies in
MLL/Meis1 leukemias in comparison with MLL/v leu-
kemias. Unlike the case for primary transplant recipi-
ents, latencies were similar irrespective of Meis1 status
since the cells had achieved full leukemic potential prior
to secondary transplant. Nevertheless, the morphologic
features and phenotypes of the respective secondary leu-
kemias were similar to those observed in the primary
mice—i.e., a less-differentiated phenotype in leukemias
coexpressing exogenous Meis1 (data not shown)—dem-
onstrating that Meis1 expression levels stably determine
LSC properties in MLL-associated AML.
Meis1 functions as a DNA-binding transcriptional
cofactor in MLL transformation
A structure/function analysis was conducted to investi-
gate whether Meis1 may require interactions with Pbx
TALE protein partners for MLL-mediated transforma-
tion. Meis1 constructs containing either deletion or
point mutations (in the M1/M2 domains) that abrogate
Pbx interaction (G.G. Wang et al. 2005) were incapable of
Figure 4. Meis1 modulates myeloid differentiation arrest, as well as CFC and LSC frequencies of MLL leukemias. (A) FACS profiles
demonstrate representative c-kit and Mac1 expression on splenocytes from mice with AML induced by transplantation of progenitors
transduced with genes indicated at the tops of the panels. Bar graph summarizes data from five mice in each category. (B) Splenocytes
from leukemic mice were analyzed for the proportion of cells with morphologic features of blasts versus differentiation following May
Grunwald Giemsa staining of cytospin preparations. Bar graph indicates the number of cells with the indicated morphologic features
for five mice in each cohort. (C) FACS-sorted Mac1+ leukemic splenocytes were cultured in methylcellulose medium for 6 d to
determine CFC frequencies. Bar graph indicates the numbers of clonogenic cells for each of five leukemias in the respective cohorts.
(D) Survival curves of sublethally irradiated mice transplanted with single AML colonies (3000 cells) plucked after 7 d in semisolid
culture and directly injected into secondary recipients, or expanded in semisolid culture for 5 d prior to injection (2.5 × 105 cells).
TALE homeoproteins in MLL leukemogenesis
GENES & DEVELOPMENT 2767
 Cold Spring Harbor Laboratory Press on August 30, 2018 - Published by genesdev.cshlp.orgDownloaded from 
rescuing MLL transformation of Meis1−/− FL cells (Fig.
6B, constructs #2 and #5), in contrast to wild-type Meis1
(Fig. 6B, construct #1). Meis1 constructs containing
homedomain mutations, which have been shown to dis-
rupt Meis1 DNA binding (G.G. Wang et al. 2005), were
also unable to complement Meis1 deficiency (Fig. 6A,B,
constructs #3 and #4). Furthermore, deletion of the con-
served C-terminal tail of Meis1 (Fig. 6A,B, construct #6),
which has been implicated in its transcriptional effector
properties, abrogated rescue of MLL transformation.
Taken together, these analyses suggest that Meis1 asso-
ciates with Pbx partners in a DNA-binding transcrip-
tional complex to mediate MLL transformation.
MLL-mediated myeloid transformation is codependent
on TALE homeodomain proteins Pbx2 and Pbx3
A genetic approach was employed to interrogate the con-
tributions of Pbx proteins in MLL leukemia. Real-time
quantitative PCR analysis showed that three Pbx genes
(Pbx1, Pbx2, and Pbx3) were expressed in myeloid pro-
genitors immortalized by MLL oncogenes (Fig. 7A; data
not shown). Pbx3 was notable for its significantly in-
creased levels (three- to eightfold) compared with control
cells transformed by E2A-HLF, consistent with increased
Pbx3 levels in human MLL AMLs (Ross et al. 2004). To-
gether, Pbx2 and Pbx3 accounted for >90% of total Pbx
transcripts, whereas Pbx1 was minimally expressed (Fig.
7B). To investigate whether specific Pbx functions were
required for MLL transformation, serial replating assays
were performed using FL cells harvested from Pbx3−/−
embryos (E14.5–E18) (Rhee et al. 2004) or bone marrow
cells isolated from adult Pbx2−/− mice (Selleri et al. 2004;
Capellini et al. 2006). MLL oncoproteins transformed the
Pbx-deficient myeloid progenitors as efficiently as wild-
type cells (Supplementary Fig. 4), indicating that MLL-
mediated transformation was not dependent on the pres-
ence of Pbx2 or Pbx3 alone.
To further reduce Pbx levels, Pbx2−/− cells trans-
formed by MLL oncogenes were secondarily transduced
with shRNAs targeting Pbx3, resulting in an ∼70%–80%
reduction of Pbx3 transcript levels (Supplementary Fig.
3). Following Pbx3 knockdown, the clonogenic potential
of Pbx2−/−/Pbx3kd MLL-transformed cells was substan-
tially decreased (>60%) when compared with Pbx2−/−
transformed cells secondarily transduced with vector
alone (Fig. 7C). This effect was specific to MLL-mediated
transformation since Pbx2−/−/Pbx3kd cells transformed
by E2A-HLF displayed no significant reduction in clono-
genic potential following Pbx3 silencing (Fig. 7C). These
results demonstrate that maintenance of MLL-mediated
transformation is specifically dependent on Pbx activity,
and further support that Meis1 functions in complex
with Pbx proteins in myeloid progenitors transformed by
MLL oncogenes.
Discussion
MLL leukemias are invariably associated with expres-
sion of Hox and TALE homeobox genes, but nevertheless
Figure 5. Altered cell cycle activity induced by Meis1 in MLL-AF10 leukemia. (A) DNA content analysis was determined by FACS
analysis of explanted leukemia cells growing in methylcellulose cultures. Bar graph summarizes data for three mice in each cohort.
(B) Expression levels of the indicated transcripts were determined by quantitative RT–PCR analysis of splenocytes isolated from
leukemic mice. Results are the mean of three leukemias in each category, and are expressed relative to transcript levels in leukemia
cells transformed by MLL-AF10.
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are clinically heterogeneous possibly reflecting differ-
ences in LSC biology and/or frequency. Misregulation of
Hox genes in MLL leukemias is likely to be critical for
LSC maintenance, as suggested by genetic loss-of-func-
tion studies (Ayton and Cleary 2003; Kumar et al. 2004;
So et al. 2004; Okada et al. 2005; J. Wang et al. 2005) and
consistent with their normal roles in HSC self-renewal
(Abramovich and Humphries 2005). However, Hox gene
misregulation alone does not recapitulate the phenotype
and biology of MLL leukemias and is unlikely to support
the high LSC frequencies recently demonstrated in a mu-
rine model of MLL-AF9 AML that are far in excess of
those previously estimated for AML in general (Somer-
vaille and Cleary 2006). Our current studies demonstrate
that TALE homeodomain proteins are essential regula-
tors of MLL transformation, and that Meis1 in particular
determines LSC frequency and potential by quantita-
tively regulating the extent of self-renewal, differentia-
tion arrest, and cycling, as well as the rate of in vivo LSC
generation from myeloid progenitors.
Meis1 is an essential regulator of LSC biology in MLL
leukemia
Genetic analyses revealed a critical dependence on
Meis1 for induction and maintenance of myeloid trans-
formation induced by several molecularly and function-
ally distinct MLL oncogenes. Notably, lack of Meis1 con-
fers a consistent and severe impairment of MLL-medi-
ated transformation in contrast to deficiencies of single
Hoxa genes, whose requirements vary for different MLL
oncogenes (Ayton and Cleary 2003; Kumar et al. 2004; So
et al. 2004; Okada et al. 2005; J. Wang et al. 2005; our
unpublished observations). Meis1 is the predominant
Meis family gene expressed in murine myeloid progeni-
tors, and its TALE protein product functions as a tran-
scriptional cofactor for multiple Hox proteins, which are
redundantly expressed. Thus, Meis1 deficiency likely re-
sults in a broad compromise of Hox transcriptional ac-
tivity, in addition to possible impacts on non-Hox-de-
pendent pathways, and consequently a more severe limi-
tation on MLL transformation than the loss of single Hox
genes.
Although Meis1 is consistently expressed and required
in murine myeloid cells transformed in vitro by different
MLL oncoproteins, its endogenous expression levels var-
ied by >20-fold and correlated with critical features of
leukemia biology and LSC frequency. Meis1 dictates the
extent of myeloid differentiation arrest induced by MLL
oncogenes as well as the fraction of leukemia cells in
cycle, and their clonogenic frequency. The similarity of
these effects to those observed for Meis1 in Hoxa9-asso-
ciated leukemogenesis (Kroon et al. 1998; G.G. Wang et
al. 2005) provides strong support for previous suggestions
that Meis1 and Hoxa9 are major effectors of MLL leuke-
mogenesis (Zeisig et al. 2004). Clonogenic frequency is a
surrogate measure of MLL LSCs (Somervaille and Cleary
2006), which are substantially increased (up to sevenfold)
in AMLs associated with hyperexpression of exogenous
Meis1. This correlates with observations that Meis1 pro-
grams expression of HSC-associated genes in Hoxa9-in-
duced leukemia (G.G. Wang et al. 2005). Our studies
substantially extend these observations by demonstrat-
ing that Meis1 quantitatively regulates functional prop-
erties of LSCs in a model of MLL leukemia.
Meis1 is rate-limiting for MLL leukemogenesis
Meis1 appears to serve two distinct but possibly interre-
lated roles in MLL leukemogenesis. In addition to its
requirement to initiate in vitro immortalization, the sig-
nificant correlation of Meis1 expression levels with la-
tencies required for development of MLL leukemias in
our mouse model supports a role for Meis1 in regulating
progression of MLL-immortalized cells to LSCs. The ge-
netic and/or epigenetic changes underlying this transi-
tion have not yet been defined, although it is character-
ized in part by acquisition of an enhanced ability to in-
teract with the bone marrow microenvironment (Shah et
al. 1998; Somervaille and Cleary 2006). A role in LSC
progression is consistent with previous observations that
Figure 6. Structure/function analysis of Meis1 requirements
in MLL transformation. (A) Western blot analysis of wild-type
and mutant Meis1 proteins expressed in retroviral packaging
Phoenix cells and detected with an anti-HA antibody. Identities
of constructs are indicated at the tops of lanes and correspond to
the schematic depictions in B. The enhanced stability of con-
struct #2 lacking Pbx interaction motifs M1/M2 has been re-
ported previously (G.G. Wang et al. 2005). (B) Myeloid transfor-
mation assay was performed using Meis1−/− FL cells cotrans-
duced with MLL-AF9 and various Meis1 constructs
schematically illustrated on the left. Results from four rounds
of plating are shown with each bar representing the mean ± SD
of the total number of myeloid colonies per 104 plated cells
derived from at least three replicates.
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hyperexpression of Meis1 markedly increased the pen-
etrance and reduced the latency for development of
Hoxa9-induced AML (Kroon et al. 1998; G.G. Wang et al.
2005). Thus, Meis1 is rate-limiting such that low levels
temper or abrogate immortalization of myeloid progeni-
tors in vitro, whereas high levels accelerate their in vivo
transition to LSCs.
The critical influence of Meis1 on LSC biology appears
to correlate with epigenetic regulation of the RB path-
way. Leukemias that developed with shortened latencies
following hyperexpression of exogenous Meis1 were as-
sociated with increased expression of the Bmi-1 gene,
which encodes a polycomb group epigenetic repressor
protein. This is consistent with previous observations
that BMI-1 levels increased during step-wise transforma-
tion and immortalization of human AML (Warner et al.
2005). However, the level of Bmi-1 mRNA increase ob-
served in our studies was relatively modest, presumably
because Bmi-1 genetically opposes MLL function
through its antagonistic effects on Hox gene expression
(Hanson et al. 1999). Bmi-1 is essential for the mainte-
nance of normal adult HSCs as well as LSCs (Lessard and
Sauvageau 2003; Park et al. 2003), consistent with the
increased LSC frequencies in MLL/Meis1 leukemias. In
this capacity, Bmi-1 represses transcription of p16Ink4a, a
CDKI at the apex of the RB pathway. Expression of
p16Ink4a inversely correlated with Meis1 and Bmi-1 lev-
els as well as the increased fraction of cycling cells in
MLL leukemias and the frequency of LSCs, which are
highly enriched for cycling cells (T.C.P. Somervaille and
M.L. Cleary, unpubl.). It was the only CDKI whose ex-
pression was consistently altered, supportive of a spe-
cific as opposed to secondary role in regulating LSC po-
tential. Preliminary studies suggest that Bmi-1 is not a
direct transcriptional target of Meis1 and is not abso-
lutely essential for MLL-mediated transformation in
vitro (P. Wong and M.L. Cleary, unpubl.), consistent
with an alternative role in regulating long-term self-re-
newal that will require assessment by long-term trans-
plantation studies. Taken together, our studies suggest
that the contributions of Meis1 in generating MLL LSCs
are mediated in part through the RB pathway by epige-
netic modulation of Ink4a expression.
Since MLL fusion proteins, in conjunction with their
essential cofactor menin, have been shown to associate
with the Meis1 promoter (Milne et al. 2005; Yokoyama
et al. 2005; Caslini et al. 2007), our observations raise the
intriguing possibility that they may vary in their abili-
ties to maintain expression of the Meis1 gene. Consis-
tent with this possibility, MLL-ENL and MLL-FKBP,
which differ in their oncogenic potencies, impose differ-
ent histone modifications at the Meis1 promoter (Milne
et al. 2005). Thus, the absolute levels of Meis1 expres-
sion may be differentially regulated by the transcrip-
Figure 7. Pbx2 and Pbx3 are required for maintenance of MLL-mediated transformation. (A) The relative expression levels of Pbx1,
Pbx2, and Pbx3 transcripts were determined by real-time PCR analysis of MLL-transformed cells (indicated below) from the fourth
round of serial replating (error bars indicate standard deviations of triplicate analyses). Results are expressed relative to levels observed
in cells transformed by E2A-HLF. (B) Bar graph indicates the total relative levels of Pbx transcripts expressed in cells transformed by
various oncogenes (indicated at bottom) from the fourth round of plating in methylcellulose cultures. The relative abundance of Pbx
transcripts was determined using the Ct value method, assuming that all primers were optimized to generate equal PCR efficiencies.
(C) Pbx2−/− myeloid progenitors transformed by various oncogenes (indicated on left) were secondarily transduced with lentiviral
vectors encoding shRNAs specific for Pbx3 (P3 #1 or P3 #2). Colony numbers are shown relative to cells secondarily transduced with
lentiviral vector alone. Error bars indicate standard deviations of at least two independent experiments.
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tional effector properties of individual MLL oncopro-
teins, which in turn dictates the rate of progression of
immortalized cells to LSCs that initiate and sustain
AML. This contrasts with Hox gene expression levels,
which do not show a similar correlation with leukemia
latencies or molecular subtypes (Supplementary Fig. 2).
Our studies suggest that TALE proteins may also criti-
cally maintain human MLL leukemia, since MEIS1
knockdown impaired the growth of leukemia cell lines.
Interestingly, the relative prevalence of different MLL
fusion genes in human leukemias is consistent with a
potential rate-limiting role for MEIS gene expression
comparable with mouse leukemias. Commonly recur-
ring MLL fusion genes such as MLL-AF9, MLL-ENL,
MLL-AF6, and MLL-AF10, which were associated with
the highest levels of Meis1 expression in our mouse
model, comprise the vast majority of spontaneous MLL-
associated human AMLs. Conversely, MLL-EB1 and
MLL-CBP, which are associated with lower Meis1 ex-
pression in our model, have only rarely been observed in
human AML (a single case for MLL-EB1) (Fu et al. 2005).
Furthermore, MLL-CBP is associated with human MDS
(Satake et al. 1997) and induces an MDS-like disorder in
mice (J. Wang et al. 2005), which are premalignant con-
ditions characterized by altered self-renewal and differ-
entiation potentials, suggesting that MLL-CBP initiates
transformation but does not readily facilitate progression
to AML. Thus, MEIS family gene expression levels in
subclinical initiated progenitors harboring MLL chromo-
somal translocations may influence the probability of
acquiring necessary secondary mutations for their con-
version into LSCs capable of inducing clinical leukemia.
MLL-mediated transformation is dependent on Pbx
function
Pbx proteins heterodimerize and bind DNA with Meis
proteins, which also regulate Pbx stability and nuclear
localization. Consistent with their biochemical interac-
tions, lack of Meis1 partially phenocopies Pbx1 defi-
ciency in hematopoietic development (DiMartino et al.
2001; Hisa et al. 2004). In MLL leukemias, Meis1 contri-
butions are dependent on the integrity of its Pbx dimer-
ization motifs. Unlike the case for Meis1, however,
single deficiencies of Pbx2 or Pbx3, the most highly ex-
pressed Pbx genes in myeloid progenitors, did not abro-
gate MLL-mediated transformation. Nevertheless, the
observed reduction of clonogenic activity in Pbx2/3
compound-deficient cells indicates that transformation
of myeloid progenitors by MLL oncoproteins is depen-
dent on Pbx function. This is a specific requirement and
not reflective of a general suppressive effect of Pbx defi-
ciency on myeloid transformation, since no impairment
of proliferation or enhanced self-renewal was observed in
Pbx2−/−Pbx3KD cells transformed by E2A-HLF, which
transforms through a Hox-independent pathway (Ayton
and Cleary 2003; So et al. 2004) and would not be ex-
pected to require Hox cofactors such as Pbx for oncogen-
esis.
Dependence on the combined contributions of Pbx2
and Pbx3 may reflect their redundant properties, consis-
tent with previous studies demonstrating that different
Pbx proteins exhibit essentially identical cooperative
DNA binding with a subset of Hox proteins in vitro
(Chang et al. 1995). Although we cannot exclude that
Pbx2 and Pbx3 make isoform-specific contributions to
MLL oncogenesis, it is more likely that single Pbx defi-
ciencies are functionally compensated by other members
of the Pbx protein family, whereas compound deficien-
cies reduce total Pbx dosage below a critical functional
threshold. In support of this, novel compound-deficient
Pbx phenotypes have recently been reported for Pbx1
and Pbx2 in limb development (Capellini et al. 2006)
despite the fact that Pbx2 deficiency alone results in no
phenotype (Selleri et al. 2004). Our data suggest that re-
duction of total Pbx (Pbx1, Pbx2, Pbx3) expression sub-
stantially below half of wild-type levels is limiting for
MLL transformation, thus establishing a critical role for
Pbx TALE proteins.
In summary, TALE homeodomain proteins are rate-
limiting for many of the biological properties that define
MLL LSCs. Meis1 in particular regulates LSC frequencies
and their origin from immortalized myeloid progenitors.
Although deregulated Hox gene expression is consis-
tently induced by MLL fusion oncogenes, Hox protein
function may be limited by the availability of TALE pro-
tein cofactors, which are more variable in their abun-
dance and correlate with leukemia latency and biologic
heterogeneity. The central role of TALE proteins in MLL
leukemia maintenance suggests their consideration as
potential therapeutic targets, which warrants further in-
vestigation.
Materials and methods
Mice
Knockout mice deficient for Pbx2 (Selleri et al. 2004), Pbx3
(Rhee et al. 2004), and Meis1 (Hisa et al. 2004) were maintained
on a C57BL/6 genetic background. C57BL/6 mice congenic for
CD45 (Ly5.1/Ly5.2) were employed for transplant studies to dis-
tinguish donor and recipient cells.
Cell lines
The human leukemia cell lines MV4.11, K562, ML2, THP-1,
SEMK2, and HB were obtained from the American Type Culture
Collection (ATCC) or generated in our laboratory and were
maintained under standard conditions.
Retroviral constructs and hematopoietic progenitor
transformation assays
Retroviral constructs encoding MLL-GAS7, MLL-AF1P, MLL-
AF6, MLL-ENL, MLL-AF9, MLL-AF10, MLL-FKHRL1, MLL-
AFX, MLL-CBP, E2A-HLF, and Meis1 have been described pre-
viously (Lavau et al. 1997, 2000; DiMartino et al. 2002; So and
Cleary 2002, 2003; So et al. 2003, 2004; Fu et al. 2005; J. Wang
et al. 2005; Somervaille and Cleary 2006). Retroviral constructs
encoding MLL-LAF4, MLL-AF5, MLL-AF6, and MLL-EB1 were
generated by insertion of the respective cDNAs or subtotal frag-
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ments with oncogenic potential (encoding LAF4 amino acids
335–1227, AF5 amino acids 727–1163, AF6 amino acids 35–137,
and EB1 amino acids 199–269;) (Imamura et al. 2002a; von Bergh
et al. 2002; Fu et al. 2005) into the MLL 5 vector using standard
cloning techniques. A dominant-negative Meis1 construct,
analogous to known dominant-negative Drosophila and Xeno-
pus Meis isoforms (Dibner et al. 2001; Inbal et al. 2001), was
generated by deletion of C-terminal amino acids 280–390,
which encode a portion of the homeodomain and downstream
residues. Retroviral constructs for Meis162–202 (Pbx1),
M1LFPLL/M2LLEL (Pbx2), HDN51S (HD1), HDN51S
RRR53-5AEE (HD2), and Meis1 341T with a deletion of a con-
served C terminus were reported previously (G.G. Wang et al.
2005). Hematopoietic transformation assays were performed es-
sentially as described previously using primary murine myeloid
progenitors harvested from bone marrow or FL (So et al. 2004).
Cells transduced with retroviral vectors were selected for stable
transduction in methylcellulose medium containing the appro-
priate antibiotic (250 µg/mL hygromycin, 1 µg/mL puromycin,
and/or 1mg/mL neomycin).
Lentivirus generation and secondary transduction
The pSicoR lentiviral vector (Ventura et al. 2004) carrying either
puromycin resistance or GFP marker genes was used for knock-
down studies. shRNAs (Supplementary Table 2) were designed
using pSicoOligomaker 1.5 (developed by A. Ventura, Jacks
Laboratory, Cambridge, MA) and cloned into HpaI–XhoI-di-
gested pSicoR. Lentiviral stocks were generated essentially as
described previously (Ventura et al. 2004). In brief, DNA con-
structs encoding lentiviral vectors (5 µg), CMV gag-pol-rev 8.74
(4 µg), and VSVG (1 µg) were cotransfected into 293T cells using
FuGENE 6 reagent (Roche Diagnostics). Supernatants were col-
lected 36–48 h after transfection, passed through a 0.4-µm filter,
and immediately incubated with immortalized cells (2 × 104 to
4 × 104) or human cell lines (1 × 105) for 12 h at 37°C. Cells
transduced with pSicoR-GFP vectors were cultured in liquid
medium for 48 h and then purified by FACS sorting for GFP
expression. Transduced mouse cells (2000 cells) were plated in
methylcellulose medium (M3231; Stem Cell Technologies)
supplemented with cytokines (20 ng/mL SCF, 10 ng/mL IL-6, 10
ng/mL IL-3, 10 ng/mL GM-CSF) or in MethoCult (H4236; Stem
Cell Technologies) for human cells. Cells transduced with
pSicoR carrying the puromycin resistance gene were plated 24 h
after transduction in 0.9% methylcellulose medium (M3231)
supplemented with cytokines and 1 µg/mL puromycin.
Leukemogenicity and long-term in vivo reconstitution assays
Transplantation experiments were performed as described pre-
viously (Lavau et al. 2000) with the following minor modifica-
tions. For cotransduction experiments, transduced progenitors
were incubated in 0.9% methycellulose medium containing cy-
tokines (20 ng/mL SCF, 10 ng/mL IL-6, 10 ng/mL IL-3) in the
presence of puromycin (1 µg/mL) and neomycin (1 mg/mL) for 5
d, and then transplanted (1 × 105 cells) together with a radiopro-
tective dose of total bone marrow cells (2 × 105) into the retro-
orbital venous sinus of 6- to 12-wk-old syngeneic C57BL/6 mice
that had been lethally irradiated with 9.0 Gy of total body 
irradiation (135Cs). When transplanted mice exhibited signs of
ill health (shortness of breath, lethargy, and hunched posture)
they were euthanized. Donor and recipient cells were distin-
guished by FACs analysis of CD45 congenic marker expression.
Necropsy tissues were fixed in buffered formalin, sectioned, and
stained with hematoxylin and eosin (H&E) for histological
analysis. Secondary transplants were performed by retro-orbital
injection of leukemia cells (3 × 103 from a single colony or
2.5 × 105 expanded in semisolid medium) into sublethally irra-
diated (450 cGy) syngeneic C57BL/6 mice.
Flow cytometry analysis
Bone marrow and spleen cells were stained with fluorochrome-
conjugated monoclonal antibodies to either c-Kit (2B8 clone),
Mac-1 (M1/70 clone), Gr-1 (RB6-8C5 clone), CD19 (1D3 clone),
B220 (RA3-6B2 clone), CD45.1 (A20.1.7), or CD45.2 (AL1-4A2).
Antibodies were purchased from PharMingen or eBioscience.
Procedures employed for cell staining and FACS analysis have
been described previously (So et al. 2004). DNA content analysis
was performed by PI staining and analyzed by FACS.
Immunoblotting
Transiently transfected Phoenix cells were harvested and lysed
in 250 µL of 2× sample buffer. Proteins from ∼20 µL of lysate
were fractionated by electrophoresis through 4% sodium do-
decyl sulfate-polyacrylamide gels and transferred to polyvinyl-
idene fluoride membranes (Bio-Rad) using Tris-glycine sodium
dodecyl sulfate transfer buffer. After blocking with 5% milk,
membranes were incubated with monoclonal antibody N4.4 di-
rected against an MLL N-terminal epitope, and then processed
for chemiluminescent detection. HA-tagged Meis1a proteins
were detected using the M2 anti-HA monoclonal antibody (Ab-
cam). Anti-actin (mouse monoclonal C4) was obtained from
Chemicon International.
Real-time quantitative PCR analysis of gene expression
cDNA was synthesized and subjected to real-time PCR as de-
scribed previously (Yokoyama et al. 2005). TaqMan probes for
the following mouse and human genes were purchased from
Applied Biosystems: Meis1 (Mm00487664_m1), Meis2
(Mm00487748_m1), Meis3 (Mm00485209_m1), Pbx1
(Mm00435507_m1), Pbx2 (Mm00479560_m1), Pbx3
(Mm00479413_m1), p19Arf (Mm01257348), Bmi1
(Mm00776122_gH), Cdkn1a (p21) (Mm01303209_m1), Cdkn1b
(p27) (Mm00438167_g1), Cdkn2a (Mm00494449_m1), Cdkn2c
(Mm00483243_m1), Cdkn4b p15 (Mm00483241_m1), -Actin
(Mm00607939_s1); MEIS1 (Hs00180020_m1), MEIS2
(Hs00542638_m1), MEIS3 (Hs00911770_g1), and ACTB
(Hs99999903 _m1). Primers for mouse p16Ink4a were designed
previously (Zhang et al. 2003) and purchased from Applied Bio-
systems. Expression levels of target transcripts relative to that
of -Actin were calculated using a standard curve and relative
quantitation methods as described in ABI User Bulletin #2.
Relative dosages of Meis, Pbx, and Hox transcripts were calcu-
lated using relative cycle time (Ct) value according to the manu-
facturer’s instructions.
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